Jove
Visualize
Contáctanos
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Videos de Conceptos Relacionados

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

4.9K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
The Cell Cycle Control System01:28

The Cell Cycle Control System

3.5K
The cell cycle regulation directs how a cell proceeds from one phase to the next and begins mitosis. The cell cycle control system includes intracellular regulatory molecules and external triggers. They provide "stop" or "advance" signals and operate at specific cell cycle stages termed checkpoints to ensure that a particular process is completed before the cell advances to the next phase.
Cyclins and cyclin-dependent kinases (Cdks) are the primary cell cycle regulators and...
3.5K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

5.7K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.7K
Negative Regulator Molecules01:23

Negative Regulator Molecules

35.9K
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
35.9K
Positive Regulator Molecules02:39

Positive Regulator Molecules

5.7K
Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
5.7K

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

Multiomic profiling of responses to clinical and novel bisphosphonates reveals extraskeletal effects on ageing related signatures.

Signal transduction and targeted therapy·2026
Same author

Molecular Solution to the Paradox of Ancient Brain Preservation.

Journal of proteome research·2026
Same author

Towards light-coupled sample preparation for time-resolved cryoEM studies.

IUCrJ·2026
Same author

Discovery of Tcf7 regulators with clonally-resolved CRISPR screens identifies Trim28 as a mediator of CD8 T cell differentiation in tumors.

bioRxiv : the preprint server for biology·2026
Same author

USP24 is a cross-reactive DUB targeting MOV10 to regulate IFN-I production.

Nature communications·2026
Same author

Multidimensional proteomics and explainable AI feature selection identify cross-platform lung cancer molecular signature in blood plasma.

Communications medicine·2026

Video Experimental Relacionado

Updated: Sep 10, 2025

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

11.1K

Orientación de los cánceres comprometidos en el punto de control G1-S con inhibidores de la ciclina A/B RxL

Shilpa Singh1, Catherine E Gleason2, Min Fang3

  • 1Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

Nature
|August 20, 2025
PubMed
Resumen

Los nuevos péptidos macrocíclicos matan selectivamente las células de cáncer de pulmón de células pequeñas (SCLC) inhibiendo las interacciones con las ciclinas. Estos medicamentos disponibles por vía oral se dirigen a los cánceres impulsados por E2F al inducir la apoptosis a través de la activación del punto de control de ensamblaje del huso.

Más Videos Relacionados

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.4K
Studying Cell Cycle-regulated Gene Expression by Two Complementary Cell Synchronization Protocols
12:02

Studying Cell Cycle-regulated Gene Expression by Two Complementary Cell Synchronization Protocols

Published on: June 6, 2017

27.6K

Videos de Experimentos Relacionados

Last Updated: Sep 10, 2025

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

11.1K
Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.4K
Studying Cell Cycle-regulated Gene Expression by Two Complementary Cell Synchronization Protocols
12:02

Studying Cell Cycle-regulated Gene Expression by Two Complementary Cell Synchronization Protocols

Published on: June 6, 2017

27.6K

Área de la Ciencia:

  • En el campo de la oncología
  • Biología molecular
  • Terapia contra el cáncer

Sus antecedentes:

  • El cáncer de pulmón de células pequeñas (SCLC) se caracteriza por mutaciones en RB1 y TP53, lo que lleva a una actividad E2F desregulada.
  • La hiperactivación de E2F, aunque es esencial para la progresión del ciclo celular, puede promover la apoptosis, presentando una vulnerabilidad terapéutica.
  • La interfaz de interacción ciclina- sustrato, específicamente los motivos RxL, ha sido un desafío.

Objetivo del estudio:

  • Desarrollar nuevos péptidos macrocíclicos permeables a las células y biodisponibles por vía oral dirigidos a los motivos de la ciclina RxL.
  • Investigar la eficacia de estos inhibidores en células cancerosas con alta actividad E2F, incluido el CPCM.
  • Aclarar los mecanismos moleculares subyacentes a los efectos anticancerígenos de estos nuevos inhibidores.

Principales métodos:

  • Desarrollo de inhibidores duales dirigidos a los motivos RxL de la ciclina A y la ciclina B (ciclina A/Bi).
  • Evaluación de la eliminación selectiva del SCLC y de otras células cancerosas con alta actividad E2F.
  • Utilizando pantallas genéticas para identificar los mecanismos de inducción de la apoptosis.
  • Investigando el papel de la ciclina B, CDK2 y la activación del punto de control de ensamblaje del husillo.
  • Evaluación de la actividad antitumoral en xenografts derivados de pacientes con CPCL resistente a la quimioterapia.

Principales resultados:

  • La ciclina A/Bi mata selectivamente al SCLC y otras células cancerosas con alta actividad E2F.
  • La apoptosis se induce a través de la activación del punto de control de ensamblaje del huso dependiente de la ciclina B y CDK2.
  • La ciclina A/ Bi bloquea las interacciones entre la ciclina A- E2F y la ciclina B- MYT1 RxL, lo que lleva a la hiperactivación de la E2F y la ciclina B.
  • Se forman complejos de ciclina B-CDK2 neomorfos, que conducen a la muerte celular mitótica.
  • La ciclina A/ Bi administrada por vía oral demostró una actividad antitumoral significativa en los trasplantes de SCLC.

Conclusiones:

  • Se han desarrollado péptidos macrocíclicos biodisponibles por vía oral (ciclina A/ Bi) que inhiben las interacciones de la ciclina RxL.
  • La ciclina A/Bi ataca eficazmente los cánceres impulsados por E2F, incluido el CPCL, al inducir la apoptosis.
  • Estos hallazgos apoyan el potencial terapéutico de la ciclina A/ Bi para el tratamiento del CPCM resistente a la quimioterapia y otros tipos de cáncer.